Trial shows slowing of Huntington’s progression for the first time
A global clinical trial for a new Huntington’s disease gene therapy has posted positive results, including 75% less progression of the disease.
AMT-130 is the first gene therapy to be tested in people with Huntington’s. This is also the first time a drug trial has reported continuing, statistically significant slowing of Huntington’s progression.
Huntington’s disease is a fatal neurodegenerative disease caused by a single genetic mutation, the cause of which was first discovered in 1993.
A total of 29 patients have completed up to 36 months of the Phase I/II clinical trial, 12 of whom were given a high dose and have a full 36 months of data.
The participants’ progression is being compared to an external cohort of people with Huntington’s disease, who are part of a long-running natural history study called Enroll-HD, to predict the extent of disease progression that would have been expected if the patients were only receiving standard care.
Results of the Huntington’s trial
The study team is reporting that people who were given a high dosage of AMT-130 have experienced 75% less disease progression after 36 months as measured by the composite Unified Huntington’s Disease Rating Scale, which incorporates motor, cognitive and functional measures, compared to a matched cohort of Enroll-HD participants.
There was also a statistically significant benefit as measured by another key scale of disease progression, Total Functional Capacity, and in three other measures of motor and cognitive function.
The researchers were also measuring participants’ levels of neurofilament light protein (NfL), a protein that is released into the spinal fluid when neurons are injured, as it is a useful marker of neuronal damage and is elevated in people with Huntington’s disease.
The scientists found that NfL levels in the spinal fluid were lower in people treated with the drug than they had been at the start of the trial, even though NfL levels would be expected to increase by 20-30% over three years. They say this suggests the course of the disease has been modified and neuronal damage slowed.
The team also found that AMT-130 is generally well-tolerated by study participants and has a manageable safety profile.
Professor Sarah Tabrizi (UCL Huntington’s Disease Research Centre, UCL Queen Square Institute of Neurology, and UK Dementia Research Institute at UCL), lead scientific advisor on the trial, said: “l am thrilled that this study of AMT-130 showed statistically significant effects on disease progression at 36 months. These groundbreaking data are the most convincing evidence in the field to date and underscore the disease-modifying effect in Huntington’s disease, where an urgent need persists. For patients, AMT-130 has the potential to preserve daily function, keep them in work longer, and meaningfully slow disease progression.”
About AMT-130
AMT-130 permanently introduces new functional DNA into a person’s cells. It consists of particles of a harmless, empty virus, plus a set of instructions encoded in custom-made DNA. The virus is injected directly into a part of the brain called the striatum which is particularly vulnerable in Huntington’s disease. This is done using stereotactic surgery, in which tiny tubes called catheters are guided to the right part of the brain, supported by live MRI images. Once in the brain, the virus particles enter the neurons and release the DNA cargo.
The AMT-130 DNA becomes a permanent addition to the neuron. It contains a set of instructions for making a molecule of RNA which has been designed to bind to the RNA that is produced when a cell is making the huntingtin protein. When AMT-130 RNA binds to the cell’s own huntingtin RNA, it summons an enzyme to destroy it. As a result, the huntingtin message is deleted and less of the protein is made – permanently.
It is expected that a single dose of AMT-130 would last for a person’s whole life.
Developers uniQure has revealed plans to submit an application to the US Food and Drug Administration (FDA) early next year requesting accelerated approval to market the drug, with applications in the UK and Europe to follow.
Dr Walid Abi-Saab, Chief Medical Officer of uniQure, commented: “We are incredibly excited about these topline results and what they may represent for individuals and families affected by Huntington’s disease. These findings reinforce our conviction that AMT-130 has the potential to fundamentally transform the treatment landscape for Huntington’s disease, while also providing important evidence supporting one-time, precision-delivered gene therapies for the treatment of neurological disorders.”
Diana Turner, Senior Digital Content Editor, DDW
